IGM Biosciences (IGMS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

IGMS Stock Forecast

IGM Biosciences stock forecast is as follows: an average price target of $18.67 (represents a 170.58% upside from IGMS’s last price of $6.90) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

IGMS Price Target

The average price target for IGM Biosciences (IGMS) is $18.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $12.00. This represents a potential 170.58% upside from IGMS's last price of $6.90.

IGMS Analyst Ratings

Buy

According to 4 Wall Street analysts, IGM Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for IGMS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

IGM Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 05, 2024	Etzer Darout	BMO Capital	$21.00	$9.46	121.99%	204.35%
Oct 01, 2024	Brian Abrahams	RBC Capital	$17.00	$16.54	2.78%	146.38%
Oct 01, 2024	Stephen Willey	Stifel Nicolaus	$25.00	$14.08	77.56%	262.32%
Oct 01, 2024	Asthika Goonewardene	Truist Financial	$12.00	$16.54	-27.45%	73.91%
Aug 15, 2024	Robert Driscoll	Wedbush	$25.00	$8.72	186.70%	262.32%
Aug 14, 2024	Michael Ulz	Morgan Stanley	$12.00	$8.72	37.61%	73.91%
May 09, 2024	Brian Abrahams	RBC Capital	$20.00	$9.34	114.13%	189.86%
Aug 23, 2022		Truist Financial	$37.00	$19.53	89.45%	436.23%
Jun 20, 2022	Joel Beatty	Robert W. Baird	$31.00	$15.24	103.41%	349.28%
Mar 30, 2022	Asthika Goonewardene	Truist Financial	$74.00	$25.85	186.27%	972.46%

The latest IGM Biosciences stock forecast, released on Dec 05, 2024 by Etzer Darout from BMO Capital, set a price target of $21.00, which represents a 121.99% increase from the stock price at the time of the forecast ($9.46), and a 204.35% increase from IGMS last price ($6.90).

IGM Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	1	4	7
Avg Price Target	$21.00	$18.75	$18.86
Last Closing Price	$6.90	$6.90	$6.90
Upside/Downside	204.35%	171.74%	173.33%

In the current month, the average price target of IGM Biosciences stock is $21.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 204.35% increase as opposed to IGM Biosciences's last price of $6.90. This month's average price target is up 12.00% compared to last quarter, and up 11.35% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 05, 2024	BMO Capital		Outperform	Initialise
Oct 01, 2024	Wedbush	Outperform	Outperform	Hold
Oct 01, 2024	RBC Capital	Outperform	Outperform	Hold
Sep 05, 2024	Wedbush	Buy	Buy	Hold
Sep 05, 2024	RBC Capital	Underperform	Underperform	Hold
Aug 15, 2024	RBC Capital	Underperform	Underperform	Hold
Aug 15, 2024	Wedbush	Neutral	Neutral	Hold
Aug 15, 2024	Wedbush	Outperform	Outperform	Hold
Aug 14, 2024	Morgan Stanley	Overweight	Overweight	Hold
May 24, 2024	Wedbush	Neutral	Neutral	Hold
May 24, 2024	RBC Capital	Underperform	Underperform	Hold
May 09, 2024	RBC Capital	Outperform	Outperform	Hold
Apr 18, 2024	Wedbush	Neutral	Neutral	Hold
Mar 08, 2024	Wedbush	Neutral	Neutral	Hold
Feb 09, 2024	RBC Capital		Outperform	Upgrade

IGM Biosciences's last stock rating was published by BMO Capital on Dec 05, 2024. The company Initialise its IGMS rating from "null" to "Outperform".

IGM Biosciences Financial Forecast

IGM Biosciences Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$509.00K	$448.00K	$522.00K	$372.00K	$331.00K	$366.00K
Avg Forecast	$5.91M	$5.91M	$5.91M	$5.91M	$5.91M	$5.91M	$5.91M	$5.91M	$3.40M	$3.40M	$3.40M	$3.40M	$287.00K	$233.33K	$54.31M	$740.63K	$699.50K	$838.33K	$797.00K	$1.48M	$304.78K	$261.00K	$51.88M
High Forecast	$12.16M	$12.16M	$12.16M	$12.16M	$12.16M	$12.16M	$12.16M	$12.16M	$6.99M	$6.99M	$6.99M	$6.99M	$531.48K	$479.90K	$54.31M	$740.81K	$1.12M	$869.50K	$1.64M	$3.04M	$626.84K	$261.00K	$51.88M
Low Forecast	$2.74M	$2.74M	$2.74M	$2.74M	$2.74M	$2.74M	$2.74M	$2.74M	$1.58M	$1.58M	$1.58M	$1.58M	$138.19K	$108.25K	$54.31M	$740.44K	$368.16K	$807.17K	$369.74K	$686.60K	$141.39K	$261.00K	$51.88M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	7	3	3	4	7	5	6	3	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.61%	0.56%	0.35%	1.22%	1.27%	0.01%

IGM Biosciences's average Quarter revenue forecast for Dec 23 based on 7 analysts is $699.50K, with a low forecast of $368.16K, and a high forecast of $1.12M. IGMS's average Quarter revenue forecast represents a 37.43% increase compared to the company's last Quarter revenue of $509.00K (Sep 23).

IGM Biosciences EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	7	3	3	4	7	5	6	3	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-66.76M	$-68.21M	$-61.71M	$-56.26M	$-59.00M	$-57.78M
Avg Forecast	$1.18M	$1.18M	$1.18M	$1.18M	$1.18M	$1.18M	$1.18M	$1.18M	$680.00K	$680.00K	$680.00K	$680.00K	$57.40K	$46.67K	$10.86M	$148.12K	$139.90K	$167.67K	$159.40K	$296.00K	$60.95K	$52.20K	$-36.66M
High Forecast	$2.43M	$2.43M	$2.43M	$2.43M	$2.43M	$2.43M	$2.43M	$2.43M	$1.40M	$1.40M	$1.40M	$1.40M	$106.30K	$95.98K	$10.86M	$148.16K	$223.84K	$173.90K	$327.84K	$608.78K	$125.37K	$52.20K	$-29.33M
Low Forecast	$548.51K	$548.51K	$548.51K	$548.51K	$548.51K	$548.51K	$548.51K	$548.51K	$315.46K	$315.46K	$315.46K	$315.46K	$27.64K	$21.65K	$10.86M	$148.09K	$73.63K	$161.43K	$73.95K	$137.32K	$28.28K	$52.20K	$-43.99M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-398.17%	-427.91%	-208.48%	-923.04%	-1130.35%	1.58%

undefined analysts predict IGMS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than IGM Biosciences's previous annual EBITDA (undefined) of $NaN.

IGM Biosciences Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	7	3	3	4	7	5	6	3	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-61.99M	$-64.42M	$-59.31M	$-48.20M	$-55.56M	$-57.97M
Avg Forecast	$-30.47M	$-29.19M	$-27.95M	$-26.76M	$-24.75M	$-23.49M	$-21.79M	$-22.23M	$-43.07M	$-26.99M	$-28.05M	$-34.12M	$-44.52M	$-48.53M	$-2.47M	$-48.85M	$-61.33M	$-68.39M	$-85.10M	$-79.88M	$-92.69M	$-84.34M	$-37.71M
High Forecast	$-9.24M	$-8.85M	$-8.47M	$-8.11M	$-7.50M	$-7.12M	$-6.61M	$-6.74M	$-13.05M	$-8.18M	$-8.50M	$-26.02M	$-28.49M	$-14.71M	$-748.47K	$-14.81M	$-50.34M	$-20.73M	$-25.79M	$-24.21M	$-28.09M	$-84.34M	$-30.17M
Low Forecast	$-72.34M	$-69.29M	$-66.35M	$-63.51M	$-58.76M	$-55.77M	$-51.73M	$-52.77M	$-102.23M	$-64.07M	$-66.59M	$-49.16M	$-61.14M	$-115.19M	$-5.86M	$-115.96M	$-66.54M	$-162.34M	$-202.01M	$-189.60M	$-220.01M	$-84.34M	$-45.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.91%	0.76%	0.74%	0.52%	0.66%	1.54%

IGM Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IGMS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

IGM Biosciences SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	7	3	3	4	7	5	6	3	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$12.51M	$12.98M	$13.00M	$11.62M	$12.66M	$12.37M
Avg Forecast	$86.35M	$86.35M	$86.35M	$86.35M	$86.35M	$86.35M	$86.35M	$86.35M	$49.66M	$49.66M	$49.66M	$49.66M	$4.19M	$3.41M	$793.33M	$10.82M	$10.22M	$12.25M	$11.64M	$21.62M	$4.45M	$3.81M	$7.96M
High Forecast	$177.60M	$177.60M	$177.60M	$177.60M	$177.60M	$177.60M	$177.60M	$177.60M	$102.14M	$102.14M	$102.14M	$102.14M	$7.76M	$7.01M	$793.33M	$10.82M	$16.35M	$12.70M	$23.94M	$44.46M	$9.16M	$3.81M	$9.56M
Low Forecast	$40.06M	$40.06M	$40.06M	$40.06M	$40.06M	$40.06M	$40.06M	$40.06M	$23.04M	$23.04M	$23.04M	$23.04M	$2.02M	$1.58M	$793.32M	$10.82M	$5.38M	$11.79M	$5.40M	$10.03M	$2.07M	$3.81M	$6.37M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.02%	1.12%	0.60%	2.61%	3.32%	1.55%

IGM Biosciences's average Quarter SG&A projection for Dec 23 is $10.22M, based on 7 Wall Street analysts, with a range of $5.38M to $16.35M. The forecast indicates a -18.31% fall compared to IGMS last annual SG&A of $12.51M (Sep 23).

IGM Biosciences EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	7	3	3	4	7	5	6	3	2	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-1.33	$-1.09	$-1.26	$-1.32
Avg Forecast	$-0.50	$-0.48	$-0.46	$-0.44	$-0.41	$-0.39	$-0.36	$-0.37	$-0.71	$-0.45	$-0.46	$-0.56	$-0.73	$-0.80	$-0.04	$-0.81	$-1.01	$-1.13	$-1.40	$-1.32	$-1.53	$-1.40	$-0.57
High Forecast	$-0.15	$-0.15	$-0.14	$-0.13	$-0.12	$-0.12	$-0.11	$-0.11	$-0.22	$-0.13	$-0.14	$-0.43	$-0.47	$-0.24	$-0.01	$-0.24	$-0.83	$-0.34	$-0.43	$-0.40	$-0.46	$-1.40	$-0.57
Low Forecast	$-1.19	$-1.14	$-1.09	$-1.05	$-0.97	$-0.92	$-0.85	$-0.87	$-1.69	$-1.06	$-1.10	$-0.81	$-1.01	$-1.90	$-0.10	$-1.91	$-1.10	$-2.68	$-3.33	$-3.13	$-3.63	$-1.40	$-0.57
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	1.01%	0.71%	0.90%	2.33%

According to undefined Wall Street analysts, IGM Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IGMS previous annual EPS of $NaN (undefined).

IGM Biosciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
HOWL	Werewolf Therapeutics	$1.64	$12.00	631.71%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
IGMS	IGM Biosciences	$7.48	$18.67	149.60%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
ERAS	Erasca	$2.63	$6.00	128.14%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
RNA	Avidity Biosciences	$32.74	$59.00	80.21%	Buy
DSGN	Design Therapeutics	$6.25	$9.67	54.72%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
IKNA	Ikena Oncology	$1.62	$1.33	-17.90%	Buy

IGMS Forecast FAQ

Is IGM Biosciences a good buy?

Yes, according to 4 Wall Street analysts, IGM Biosciences (IGMS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of IGMS's total ratings.

What is IGMS's price target?

IGM Biosciences (IGMS) average price target is $18.67 with a range of $12 to $25, implying a 170.58% from its last price of $6.9. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will IGM Biosciences stock go up soon?

According to Wall Street analysts' prediction for IGMS stock, the company can go up by 170.58% (from the last price of $6.9 to the average price target of $18.67), up by 262.32% based on the highest stock price target, and up by 73.91% based on the lowest stock price target.

Can IGM Biosciences stock reach $10?

IGMS's average twelve months analyst stock price target of $18.67 supports the claim that IGM Biosciences can reach $10 in the near future.

What is IGM Biosciences's current price target trend?

1 Wall Street analyst forecast a $21 price target for IGM Biosciences (IGMS) this month, up 204.35% from its last price of $6.9. Compared to the last 3 and 12 months, the average price target increased by 171.74% and increased by 173.33%, respectively.

What are IGM Biosciences's analysts' financial forecasts?

IGM Biosciences's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $23.65M (high $48.63M, low $10.97M), average EBITDA is $4.73M (high $9.73M, low $2.19M), average net income is $-92.273M (high $-27.967M, low $-219M), average SG&A $345.4M (high $710.39M, low $160.24M), and average EPS is $-1.521 (high $-0.461, low $-3.611). IGMS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $23.65M (high $48.63M, low $10.97M), average EBITDA is $4.73M (high $9.73M, low $2.19M), average net income is $-114M (high $-34.665M, low $-271M), average SG&A $345.4M (high $710.39M, low $160.24M), and average EPS is $-1.885 (high $-0.571, low $-4.476).

Did the IGMS's actual financial results beat the analysts' financial forecasts?

Based on IGM Biosciences's last annual report (Dec 2023), the company's revenue was $2.13M, which missed the average analysts forecast of $3.81M by -44.17%. Apple's EBITDA was $-263M, missing the average prediction of $762.96K by -34631.29%. The company's net income was $-246M, missing the average estimation of $-295M by -16.38%. Apple's SG&A was $50.07M, missing the average forecast of $55.72M by -10.14%. Lastly, the company's EPS was $-0.0047, missing the average prediction of $-4.858 by -99.90%. In terms of the last quarterly report (Sep 2023), IGM Biosciences's revenue was $509K, missing the average analysts' forecast of $838.33K by -39.28%. The company's EBITDA was $-66.76M, missing the average prediction of $167.67K by -39917.26%. IGM Biosciences's net income was $-61.989M, missing the average estimation of $-68.392M by -9.36%. The company's SG&A was $12.51M, beating the average forecast of $12.25M by 2.14%. Lastly, the company's EPS was $-0.001, missing the average prediction of $-1.127 by -99.91%